Fusing thymosin alpha-1 with a tumor-homing peptide created a modified version that accumulated better in tumors and showed stronger anticancer and immune-boosting effects in mice.
Enhanced tumor accumulationThe Tα1-iRGD fusion peptide accumulated more effectively in tumors and attached better to melanoma and lung cancer cells than unmodified thymosin alpha-1
What the researchers found
A modified version of thymosin alpha-1 (Tα1) fused with the tumor-homing peptide iRGD showed stronger antitumor activity than standard Tα1 against both melanoma and lung cancer in mice. The fusion peptide Tα1-iRGD promoted T-cell activation and increased CD86 expression on immune cells, accumulated more effectively in tumors, reduced tumor blood vessel density, and attached more readily to B16F10 melanoma and H460 lung cancer cells.
The modified peptide also demonstrated significantly better immunomodulatory activity in hydrocortisone-induced immunosuppression models, suggesting enhanced ability to boost immune function even under immunosuppressive conditions.
Why it matters
Thymosin alpha-1 is already used clinically as an immune-boosting peptide, but its effects are broad and non-specific. By fusing it with the tumor-homing peptide iRGD, researchers created a version that specifically targets tumors while retaining its immune-stimulating properties. This targeted approach could make thymosin alpha-1 more effective as a cancer therapy with potentially fewer off-target effects.
The numbers in context
Tested against B16F10 melanoma and H460 lung cancer cells · Enhanced CD86 expression · Reduced tumor vessel density · Helical conformation in both Tα1 and Tα1-iRGD
How the study worked
Researchers designed a fusion protein combining thymosin alpha-1 with the tumor-homing peptide iRGD. They tested it in multiple mouse models (BALB/c, C57BL, ICR, and nude mice) with melanoma and lung cancer tumors. They assessed T-cell activation, CD86 expression, tumor accumulation, tumor vessel density, cell attachment, and immunomodulatory activity in hydrocortisone-induced immunosuppression models. Circular dichroism spectroscopy was used to analyze protein structure.
Who was studied
Multiple mouse strains (BALB/c, C57BL, ICR, nude mice) bearing melanoma (B16F10) and lung cancer (H460) tumors
What this study cannot tell us
This was an animal study using mouse tumor models, and human efficacy remains untested. The specific dosing, treatment schedules, and long-term safety were not detailed in the abstract. The hydrocortisone immunosuppression model is a simplified representation of clinical immunosuppression.
How to read the evidence
This is a preclinical study using multiple mouse models with both in vivo tumor experiments and structural analysis. The evidence is strong for the animal models tested but requires human clinical trials for translation.
When this study was published
Published in 2018, this study is relatively recent. The thymosin alpha-1 field continues to evolve with new modifications and combination approaches being explored.
The bigger picture
Peptide-based cancer immunotherapy is a rapidly growing field. This study demonstrates that combining an established immunomodulatory peptide with a tumor-targeting peptide can create a more effective hybrid therapeutic. The approach of adding targeting peptides to existing therapeutic peptides could be broadly applicable to improving other peptide drugs.
Questions still open
- How does Tα1-iRGD compare to existing checkpoint inhibitor immunotherapies in terms of antitumor efficacy?
- What is the optimal dosing regimen and route of administration for Tα1-iRGD in clinical settings?
- Could the iRGD targeting strategy be applied to other therapeutic peptides to improve their tumor specificity?
Common questions
What is thymosin alpha-1 and what is it used for?
What does the iRGD targeting peptide do?
Read the original research
Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
International journal of pharmaceutics, 547(1-2), 611-620
Citation
Wang, Fanwen; Li, Bin; Fu, Pengcheng; Li, Qingqing; Zheng, Heng; Lao, Xingzhen. (2018). Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.. International journal of pharmaceutics, 547(1-2), 611-620. https://doi.org/10.1016/j.ijpharm.2018.06.041